MINUTES OF THE 181st MEETING OF THE REVIEW COMMITTEE ON GENETIC MANIPULATION (RCGM) HELD ON 05.03.2020 IN THE DEPARTMENT OF BIOTECHNOLOGY

The Chairman, RCGM extended a formal welcome to the members of the RCGM for the 181st meeting and initiated the process of the meeting. The list of participants is given at Annexure-I.

2. The Committee adopted the minutes and recommendations of the 180th meeting of the RCGM held on 06.02.2020.

3. On action taken report, the Member-Secretary informed that during the 180th meeting of the RCGM, a total of 8 applications including information items were considered and the Secretariat is in the process of issuing requisite permit letters based on the recommendations of the RCGM.

4. Proposals considered

4.1 Applications in the area of pharmaceuticals

The Committee considered applications to import reassortant Influenza strain; to conduct preclinical toxicity studies on Filgrastim biosimilar, Gene therapy product for Haemophilia B, recombinant Teriparatide peptide, Nivolumab biosimilar, Pegylated Epoietin; pre-clinical toxicity study reports on Denosumab biosimilar, Rituximab biosimilar, recombinant Insulin aspart, recombinant Insulin Glargine, and recombinant Rituximab. After deliberation on each application including information items, appropriate decision was taken by the RCGM.

4.2 Applications in the area of Agriculture

The Committee considered applications to conduct confined field trials for event selection of GE cotton and GE brinjal; inventory and utilization report of GE maize seeds; Central Compliance Committee reports on Event Selection Trial of GE mustard and Biosafety Resaech Trial of GE cotton. After deliberation on each application including information items, appropriate decision was taken by the RCGM.

5. IBSC Reports

The Committee considered minutes submitted by twenty IBSCs and thirty four annual compliance reports, and appropriate decision was taken by the RCGM.

6. Other items

The Committee considered revised draft IBSC Handbook and E learning modules, and appropriate decision was taken by the RCGM.

No other transaction took place and the meeting ended with vote of thanks to the chair.

The Minutes are approved.

(Dr. Rakesh Kumar Mishra)
Chairman, RCGM
List of Participants:

1. Dr. Rakesh Kumar Mishra, Director-CCMB, Hyderabad - Chairman
2. Dr. Kuldeep Singh, Director, ICAR- NBPGR, New Delhi - Co-Chair (Agri)
3. Dr. Gururaj Katti, Principal Scientist & Head, ICAR- IIRR, Hyderabad - Member
4. Dr. S. K. Rath, Principal Scientist, CSIR- CDRI, Lucknow - Member
5. Dr. P. V. Mohanan, Scientist ‘G’, SCTIMST, Thiruvananthapuram - Member
6. Dr. Rajnish Kumar Chaturvedi, Senior Scientist, CSIR- IITR, Lucknow - Member
7. Dr. Rajesh S. Gokhale, Staff Scientist- VII, NII, New Delhi - Member
8. Dr. K.G.Tirumurugaaan, Professor, TANUVAS, Chennai - Member
9. Dr. Shilpi Paul, Scientist E, SERB - Nominee-DST
10. Dr. Alka Sharma, Scientist-G, & Nodal Officer (Biopharma), DBT, New Delhi - Member
11. Dr. A.K. Rawat, Scientist- G & Nodal Officer (Agri.), DBT, New Delhi - Member
12. Dr. Vanga Siva Reddy, CSO, BSU, New Delhi - Special Invitee
13. Dr. Nitin K. Jain, Scientist-F, DBT - Member Secretary
14. Dr. Gandharva Nagpal - Scientist C, DBT

Biosafety Support Unit:

15. Dr. Sangeeta Agarwal, Chief (Agriculture)
16. Dr. Poornam Vishwakarma, Scientist
17. Dr. Manpreet Kaur, Scientist
18. Dr. Reema Sharma, Scientist

Others:

19. Mr. Yogananth Rajendran, Cadila Healthcare Ltd.
20. M/s. Sujata Halder, Cadila Healthcare Ltd.
21. Dr. Jitendra Patel, Cadila Healthcare Ltd.
22. Mr. M Saravanan, Vipragen Biosciences Pvt. Ltd.
23. Mr. Harsha C., Samarth Life Sciences Pvt. Ltd.
24. Mr. K.N. Prasad, Samarth Life Sciences Pvt. Ltd.
25. Mr. G. Reddiprasad, Samarth Life Sciences Pvt. Ltd.
26. Dr. Alok Chaturvedi, Intas Pharmaceuticals Ltd.
27. Mr. Ronak Patel, Intas Pharmaceuticals Ltd.
28. Mr. Ramesh Sharma, Intas Pharmaceuticals Ltd.
29. Dr. Lakshmikanth Gandikota, Intas Pharma Ltd.
30. Dr. Dwarakesh Parihar, Bioseed Research India, a division of DCM Shiriram Ltd.